ANGLE plc
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 sys… Read more
ANGLE plc (ANPCF) - Net Assets
Latest net assets as of June 2025: $11.69 Million USD
Based on the latest financial reports, ANGLE plc (ANPCF) has net assets worth $11.69 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.08 Million) and total liabilities ($6.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $11.69 Million |
| % of Total Assets | 64.66% |
| Annual Growth Rate | 11.68% |
| 5-Year Change | -46.31% |
| 10-Year Change | 82.78% |
| Growth Volatility | 390.81 |
ANGLE plc - Net Assets Trend (2000–2024)
This chart illustrates how ANGLE plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ANGLE plc (2000–2024)
The table below shows the annual net assets of ANGLE plc from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $18.44 Million | -19.61% |
| 2023-12-31 | $22.94 Million | -42.74% |
| 2022-12-31 | $40.06 Million | -0.66% |
| 2021-12-31 | $40.33 Million | +17.43% |
| 2020-12-31 | $34.34 Million | +77.62% |
| 2018-12-31 | $19.34 Million | +21.73% |
| 2017-12-31 | $15.88 Million | +80.38% |
| 2016-12-31 | $8.81 Million | +68.21% |
| 2015-12-31 | $5.24 Million | -48.11% |
| 2014-12-31 | $10.09 Million | +82.94% |
| 2013-12-31 | $5.51 Million | -18.73% |
| 2012-12-31 | $6.79 Million | +54.03% |
| 2011-12-31 | $4.41 Million | -2.80% |
| 2010-12-31 | $4.53 Million | +9.07% |
| 2009-12-31 | $4.16 Million | +8.77% |
| 2008-12-31 | $3.82 Million | -47.08% |
| 2007-12-31 | $7.22 Million | +26.75% |
| 2006-12-31 | $5.70 Million | -60.66% |
| 2005-12-31 | $14.48 Million | 0.00% |
| 2004-12-31 | $14.48 Million | +31.78% |
| 2003-12-31 | $10.99 Million | +1912.64% |
| 2002-12-31 | $546.00K | -39.93% |
| 2001-12-31 | $909.00K | -30.13% |
| 2000-12-31 | $1.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ANGLE plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13144600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $151.59 Million | 822.01% |
| Total Equity | $18.44 Million | 100.00% |
ANGLE plc Competitors by Market Cap
The table below lists competitors of ANGLE plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Firma Oponiarska DĘBICA SA
WAR:DBC
|
$34.43 Million |
|
Lotus Bakeries NV
PINK:LOTBY
|
$34.44 Million |
|
Cardlytics Inc
NASDAQ:CDLX
|
$34.46 Million |
|
GenoFocus Inc
KQ:187420
|
$34.47 Million |
|
Solasia Pharma K.K
F:9SO
|
$34.42 Million |
|
Mithril Silver and Gold Ltd
AU:MTH
|
$34.42 Million |
|
Kpx Green Chem
KO:083420
|
$34.41 Million |
|
Fosterville South Exploration Ltd
OTCQX:FSXLF
|
$34.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ANGLE plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 22,939,000 to 18,441,000, a change of -4,498,000 (-19.6%).
- Net loss of 14,225,000 reduced equity.
- New share issuances of 8,631,000 increased equity.
- Other factors increased equity by 1,096,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.22 Million | -77.14% |
| Share Issuances | $8.63 Million | +46.8% |
| Other Changes | $1.10 Million | +5.94% |
| Total Change | $- | -19.61% |
Book Value vs Market Value Analysis
This analysis compares ANGLE plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.82x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.24x to 2.82x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $0.13 | $0.16 | x |
| 2001-12-31 | $0.09 | $0.16 | x |
| 2002-12-31 | $0.05 | $0.16 | x |
| 2003-12-31 | $0.93 | $0.16 | x |
| 2004-12-31 | $0.82 | $0.16 | x |
| 2005-12-31 | $0.82 | $0.16 | x |
| 2006-12-31 | $0.21 | $0.16 | x |
| 2007-12-31 | $0.27 | $0.16 | x |
| 2008-12-31 | $0.14 | $0.16 | x |
| 2009-12-31 | $0.15 | $0.16 | x |
| 2010-12-31 | $0.16 | $0.16 | x |
| 2011-12-31 | $0.13 | $0.16 | x |
| 2012-12-31 | $0.17 | $0.16 | x |
| 2013-12-31 | $0.13 | $0.16 | x |
| 2014-12-31 | $0.23 | $0.16 | x |
| 2015-12-31 | $0.10 | $0.16 | x |
| 2016-12-31 | $0.14 | $0.16 | x |
| 2017-12-31 | $0.17 | $0.16 | x |
| 2018-12-31 | $0.14 | $0.16 | x |
| 2020-12-31 | $0.19 | $0.16 | x |
| 2021-12-31 | $0.18 | $0.16 | x |
| 2022-12-31 | $0.16 | $0.16 | x |
| 2023-12-31 | $0.09 | $0.16 | x |
| 2024-12-31 | $0.06 | $0.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ANGLE plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -77.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -497.03%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 1.38x
- Recent ROE (-77.14%) is below the historical average (-49.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -101.92% | -113.14% | 0.71x | 1.27x | $-1.46 Million |
| 2001 | -104.62% | -53.25% | 1.39x | 1.42x | $-1.04 Million |
| 2002 | -64.47% | -17.75% | 1.89x | 1.92x | $-406.60K |
| 2003 | 20.85% | 79.66% | 0.24x | 1.10x | $1.19 Million |
| 2004 | -17.44% | -61.72% | 0.25x | 1.11x | $-3.97 Million |
| 2005 | -17.44% | -61.72% | 0.25x | 1.11x | $-3.97 Million |
| 2006 | -159.87% | -269.71% | 0.44x | 1.36x | $-9.68 Million |
| 2007 | 16.76% | 31.24% | 0.42x | 1.27x | $487.90K |
| 2008 | -94.09% | -70.99% | 0.93x | 1.43x | $-3.98 Million |
| 2009 | -1.06% | -1.79% | 0.45x | 1.30x | $-459.60K |
| 2010 | -7.73% | -14.63% | 0.46x | 1.15x | $-812.20K |
| 2011 | -56.43% | -183.72% | 0.27x | 1.13x | $-3.04 Million |
| 2012 | -12.20% | -89.34% | 0.13x | 1.06x | $-1.58 Million |
| 2013 | -17.97% | -132.83% | 0.13x | 1.04x | $-1.66 Million |
| 2014 | -33.12% | 0.00% | 0.00x | 1.03x | $-4.68 Million |
| 2015 | -80.02% | -1355.40% | 0.05x | 1.10x | $-5.50 Million |
| 2016 | -66.03% | -1318.67% | 0.05x | 1.10x | $-7.56 Million |
| 2017 | -45.69% | -1203.18% | 0.03x | 1.11x | $-9.21 Million |
| 2018 | -46.25% | -1318.88% | 0.03x | 1.19x | $-10.88 Million |
| 2020 | -33.79% | -1523.10% | 0.02x | 1.14x | $-15.04 Million |
| 2021 | -37.22% | -1481.93% | 0.02x | 1.17x | $-19.05 Million |
| 2022 | -54.13% | -2083.19% | 0.02x | 1.24x | $-25.69 Million |
| 2023 | -87.76% | -920.95% | 0.07x | 1.36x | $-22.43 Million |
| 2024 | -77.14% | -497.03% | 0.11x | 1.38x | $-16.07 Million |
Industry Comparison
This section compares ANGLE plc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,013,523,841
- Average return on equity (ROE) among peers: -16.15%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ANGLE plc (ANPCF) | $11.69 Million | -101.92% | 0.55x | $34.42 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |